Updated Results of a Phase II Study of Elotuzumab/Lenalidomide/Low-Dose Dexamethasone for Relapsed/Refractory MM


Updated Results of a Phase II Study of Elotuzumab/Lenalidomide/Low-Dose Dexamethasone for Relapsed/Refractory MM
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with A Keith Stewart, MBChB (1/9/13)
Richardson PG et al. A Phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): Updated results. Proc ASH 2012;Abstract 202.

Dr Stewart is Dean for Research at the Mayo Clinic in Arizona, is Consultant in the Division of Hematology/Oncology and holds the Vasek and Anna Maria Polak Professorship in Cancer Research in Scottsdale, Arizona.